Inhibition of pro-survival BCL-2 family members by BH3 mimetics has been shown to be effective in treating patients with AML and lead to the FDA approval of Venetoclax.27,28 However, in the trial only 19% of the relapsed/refractory AML patients responded favorably to Venetoclax monotherapy. Here, BCL2 is linked to acute myeloid leukemia.